Allogene Therapeutics Inc., of South San Francisco, said it closed its IPO of 20.7 million shares, including 2.7 million shares sold to underwriters exercising their full overallotment option, priced at $18 each. Gross proceeds totaled $372.6 million. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen and Co. LLC and Jefferies LLC acted as the joint book-running managers.